Peptides DB
Research-centric peptide and protocol reference hub

Cyclic Glycine-Proline (cGP) record · updated 18h ago

Neuro & moodGrade C · preclinicalResearch use only
All 12 studiesJump to the evidenceCompare
What is Cyclic Glycine-Proline (cGP) used for?

Cyclic Glycine-Proline (cGP) is a cyclic dipeptide that is derived from the peptide insulin-like growth factor 1 (IGF-1). It is characterized by its unique cyclic structure, which is believed to enhance its stability and bioavailability compared to linear peptides. cGP is primarily studied for its potential neuroprotective effects and its role in modulating cognitive aging, making it a subject of interest in neurobiology and gerontology.

Primarily researched for · Neuro & mood

Development stage

where Cyclic Glycine-Proline (cGP) sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 77 registered trials. It describes the research record, not a recommendation.

Identity
NameCyclic Glycine-Proline (cGP)
Chain length—
Molecular weight154.2 Da
FormulaC7H10N2O2
Structure typeSmall molecule
ClassNeuro
Research levelPreclinical
Discovered byCurated master list · 2026

Mass and formula from PubChem CID 126154. No verified residue count for this compound.

Pharmacology
Mechanism—
Route—
Half-life—
Time to peak—
Duration—
Extraction confidence—
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Aug 19, 2026. How this works →
Research stats
Total studies12
Human / animal / cellular0 / 3 / 8
Highest trial phasePreclinical
Years covered2020–2026
Latest study2mo ago
Publication history
20202026
Research funding
5 NIH projects · $1.1M awarded · through FY2011
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

12 rowsOpen in the library →
StudyTypeYearSummary depth
Screening of Stereochemically Defined 2,5-Diketopiperazines Identifies Autophagy Inducers without mTORC1 Suppression
FindingNot reported in abstract.
In vitro2026Full text read0.70
Development of a novel electrochemical impedance spectroscopy-based biosensor for bone formation-resorption biomarker determination in body fluids.
Findingβ-CTX detection range: 10-60 pg mL^-1, LOD: 2.9 pg mL^-1
In vitro2026Full text read0.70
Reduced mediators released by cyanobacteria during exoelectrogenesis detected using differential pulse voltammetry.
FindingMultiple light-enhanced oxidation peaks at 0.1-0.65 V vs. SCE.
In vitro2026Full text read0.80
Rational design of a sulfonium-stabilized cyclic temporin-SHf as a potential food preservative.
FindingTen-fold increase in antimicrobial potency relative to native peptide.
In vitro2026Full text read0.70
Glycodeoxycholic and deoxycholic bile acids impair recognition and spatial memory in adult mice, and reduce central CREB-BDNF signaling and cytokine expression with neuroanatomical specificity.
FindingGDCA impaired recognition memory after 10 days.
Animal2026Full text read0.80
Discovery of a novel STING-binding peptide associated with reduced cGAMP-induced inflammatory gene expression.
FindingPeptide-1 Kd = 0.15 ± 0.01 μM
In vitro2026Full text read0.80
ZIF-8 nanoplatform coordinating Zn<sup>2+</sup> overload and STING activation for enhanced prostate cancer immunotherapy.
TakeawayA ZIF-8 nanoplatform shows potential in enhancing prostate cancer immunotherapy through Zn<sup>2+</sup> overload and STING activation, but human studies are needed.
Animal2026Full text read0.70
Comparative innate immune responses across major RNA and DNA viral infections: Mechanisms, immunopathology, and therapeutic perspectives.
TakeawayInnate immune responses differ significantly between RNA and DNA viruses, influencing infection severity and therapeutic strategies.
review2026Full text read0.80
Maternal treatment of cyclic glycine-proline improves memory, astrocyte plasticity, vascularization and GluR-1 expression of adult offspring in rats
FindingHigher path efficiency of entry to the platform zone in cGP-treated offspring (p=0.03)
Animal2020Full text read0.70
Discovery of hybrid Glypromate conjugates with neuroprotective activity against paraquat-induced toxicity.
Finding15a outperformed Glypromate with a 2-fold enhancement, p < 0.05.
In vitro2024Full text read0.70
Quantitative Monitoring of Cyclic Glycine-Proline in Marine Mangrove-Derived Fungal Metabolites.
Finding67.45 ± 1.11 ng/mL cGP content in <i>Penicillium pedernalense</i>.
In vitro2023Full text read0.70
Untargeted metabolomics identifies a bacterial cyclic dipeptide that induces resistance to a rust fungus of beans.
Finding90% reduction in disease severity in beans pretreated with cWP.
In vitro2025Partial text0.40

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Cyclic Glycine-Proline (cGP) will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Cyclic Glycine-Proline (cGP) is discussed should be drawn from it.